2 weeks Ago By ABMN Staff
Rhumbline Advisers lifted its holdings in shares of ProKidney Corp. ( NASDAQ:PROK – Free Report ) by 8.8% during the 2nd quarter, HoldingsChannel.
com reports. The firm owned 76,190 shares of the company’s stock after buying an additional 6,181 shares during the period. Rhumbline Advisers’ holdings in ProKidney were worth $187,000 as of its most recent SEC filing.
Separately, Bank of New York Mellon Corp increased its position in ProKidney by 44.6% during the second quarter. Bank of New York Mellon Corp now owns 179,236 shares of the company’s stock worth $441,000 after buying an additional 55,266 shares during the last quarter.
Institutional investors own 51.59% of the company’s stock. ProKidney Stock Performance Shares of NASDAQ:PROK opened at $1.
86 on Monday. ProKidney Corp. has a 52-week low of $1.
12 and a 52-week high of $4.98. The company has a market cap of $426.
58 million, a P/E ratio of -3.26 and a beta of 1.10.
The stock’s 50-day moving average is $2.26 and its 200-day moving average is $2.40.
Wall Street Analysts Forecast Growth Several analysts have recently issued reports on the company. Guggenheim initiated coverage on ProKidney in a research note on Tuesday, September 10th. They set a “buy” rating and a $6.
00 price target for the company. Jefferies Financial Group decreased their target price on ProKidney from $15.00 to $6.
00 and set a “buy” rating for the company in a research report on Monday, June 10th. Finally, Bank of America dropped their price target on shares of ProKidney from $4.00 to $3.
00 and set a “neutral” rating on the stock in a research report on Wednesday, September 4th. View Our Latest Research Report on PROK Insider Buying and Selling In other ProKidney news, insider Darin J. Weber sold 16,412 shares of the stock in a transaction on Thursday, September 19th.
The shares were sold at an average price of $2.50, for a total value of $41,030.00.
Following the completion of the sale, the insider now directly owns 103,480 shares of the company’s stock, valued at approximately $258,700. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website . 41.
49% of the stock is currently owned by insiders. About ProKidney ( Free Report ) ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States.
The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. Featured Stories Want to see what other hedge funds are holding PROK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ProKidney Corp.
( NASDAQ:PROK – Free Report ). Receive News & Ratings for ProKidney Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProKidney and related companies with MarketBeat.com's FREE daily email newsletter .
.
